After years of R&D efforts VAR2 Pharma is finally ready to present our novel proprietary cancer targeting antibodies. The antibodies targeting oncofetal chondroitin sulfate have demonstrated very high broad solid tumor specificity and preclinical PoC for antibody-drug conjugate (ADC) applications in different cancer disease models. We are now looking for partners in the pharmaceutical industry […]
